Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 10/30 11:55:00 am
412.275 DKK   -3.01%
01:30pNOVO NORDISK A/S : Investor presentation
PU
12:10pNOVO NORDISK : Berenberg gives a Neutral rating
MD
11:43aGLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- products for treating diabetes and obesity (84.3%);

- hemophilia treatment products (8.4%): mainly injections of protein;

- growth hormones (6%): used for treatment of growth deficiencies in children;

- hormone replacement products (1.3%): used for treatment of the menopause and prevention of osteoporosis.

Net sales are distributed geographically as follows: Europe (19.1%), the United States (47.1%), North America (2.5%), Africa/Asia/Middle East/Oceania (11.5%), China (10.5%), Japan and Korea (5.3%) and Latin America (4%).

Number of employees : 43 258 people.
Sales per Business
20182019Delta
DKK (in Million)%DKK (in Million)%
Diabetes and Obesity Care93,90484%102,84084.3% +9.52%
Biopharm17,92716%19,18115.7% +7%
Sales per region
20182019Delta
DKK (in Million)%DKK (in Million)%
United States54,48848.7%57,48647.1% +5.5%
Europe21,67919.4%23,26219.1% +7.3%
Africa, Asia, Middle East & Oceania12,15310.9%14,08911.5% +15.93%
China11,28510.1%12,84410.5% +13.81%
Japan & Korea5,7975.2%6,4535.3% +11.32%
Latin America4,0093.6%4,9164% +22.62%
Canada2,4202.2%2,9712.4% +22.77%
Managers
NameAgeSinceTitle
Lars Fruergaard Jorgensen532017President & Chief Executive Officer
Helge Lund562018Chairman
Maziar Mike Doustdar492016Executive Vice President-International Operations
Karsten Munk Knudsen472018Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, Dr.59-Chief Science Officer & Executive Vice President
Stephen Gough, Dr.-2015Global Chief Medical Officer
Anne Marie Handrup Kverneland642000Director
Stig Strøbæk561998Director
Elizabeth Anne Hewitt632012Independent Director
Jeppe Fonager Christiansen602013Vice Chairman
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 20 537,000,000 0 0.0% 0 0.0% 75.1%
Stock B 1 1,812,564,000 1,764,557,450 97.4% 48,000,000 2.6%
Shareholders
NameEquities%
Novo Nordisk Fonden 135,764,000 7.49%
The Vanguard Group, Inc. 48,666,199 2.68%
Norges Bank Investment Management 44,164,903 2.44%
Alecta Pension Insurance Mutual 27,085,444 1.49%
Novo Nordisk A/S 25,747,394 1.42%
BlackRock Fund Advisors 25,259,915 1.39%
Fundsmith LLP 21,020,456 1.16%
BlackRock Investment Management (UK) Ltd. 17,802,968 0.98%
Handelsbanken Fonder AB 15,325,041 0.85%
Capital Research & Management Co. (World Investors) 15,088,274 0.83%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 25,747,3941.42%1,782,067,255 USD
NNIT A/S (NNIT) 4,375,00017.5%90,839,263 USD
Innate Pharma (IPH) 9,817,54612.4%37,392,775 USD
Markets and indexes
-
- Main Market Large
- OMXC 20 / Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  NOVOB:DC
- Reuters Code :  NOVOb.CO
- Datastream Code :  DK:NON
Company contact information
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsvaerd


Phone : +45 44 44 88 88
Fax : +45 44 49 05 55
web site : http://www.novonordisk.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Novo Nordisk A/S
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S14.60%154 639
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518
ABBVIE INC.-8.89%142 369
ASTRAZENECA PLC3.54%133 389
BRISTOL-MYERS SQUIBB COMPANY-9.77%130 548
AMGEN INC.-9.64%126 808
ELI LILLY AND COMPANY0.85%120 167
SANOFI-12.71%114 606
GLAXOSMITHKLINE PLC-26.69%83 782
JIANGSU HENGRUI MEDICINE CO., LTD.21.81%71 647
CHUGAI PHARMACEUTICAL CO., LTD.19.67%64 796
ALLERGAN PLC0.97%63 659
TAKEDA PHARMACEUTICAL COMPANY LIMITED-25.23%51 397
DAIICHI SANKYO COMPANY, LIMITED14.06%50 580
BAYER AG-43.98%46 721
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED33.40%26 873
ASTELLAS PHARMA INC.-23.26%25 942